ESPR - Esperion Therapeutics, Inc. - SEC Form 4 Insider Trading Screener
23 results - 
- 
- 
- 
- 
- 
- - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-03-11 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $43.00 | +2,500 | 111,998 | +2% | +$107,500 | ||||||
2020-02-28 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $49.00 | +5,000 | 109,498 | +5% | +$245,000 | ||||||
2020-01-23 | ESPR | Biotech Target N V | 10% | P - Purchase | $52.12 | +20,000 | 3,747,964 | +1% | +$1,042,398 | ||||||
2019-11-06 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $36.98 | +5,000 | 83,663 | +6% | +$184,900 | ||||||
2019-11-06 | ESPR | Biotech Target N V | 10% | P - Purchase | $37.30 | +75,000 | 3,727,964 | +2% | +$2,797,560 | ||||||
| M | 2019-09-04 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $34.55 | +7,500 | 78,663 | +11% | +$259,107 | |||||
2019-09-04 | ESPR | Biotech Target N V | 10% | P - Purchase | $33.78 | +80,000 | 3,652,964 | +2% | +$2,702,208 | ||||||
2019-08-01 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $39.56 | +5,000 | 71,163 | +8% | +$197,800 | ||||||
2019-07-23 | ESPR | Biotech Target N V | 10% | P - Purchase | $42.65 | +50,000 | 3,572,964 | +1% | +$2,132,565 | ||||||
2019-06-28 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $46.00 | +5,000 | 66,163 | +8% | +$230,000 | ||||||
2019-04-03 | ESPR | Bartram Richard | CFO | S - Sale | $42.88 | -8,000 | 11,092 | -42% | -$343,045 | ||||||
2019-03-29 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $40.00 | +5,000 | 61,163 | +9% | +$200,000 | ||||||
2019-03-20 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $43.48 | +5,000 | 56,163 | +10% | +$217,400 | ||||||
2019-03-19 | ESPR | Vitullo Nicole | Dir | S - Sale | $44.73 | -15,329 | 8,319 | -65% | -$685,596 | ||||||
2019-03-14 | ESPR | Biotech Target N V | 10% | P - Purchase | $49.89 | +50,000 | 3,522,964 | +1% | +$2,494,355 | ||||||
2019-03-14 | ESPR | Mayleben Timothy M | Pres, CEO | P - Purchase | $48.73 | +5,000 | 51,163 | +11% | +$243,650 | ||||||
2019-03-12 | ESPR | Newton Roger S | Dir | S - Sale | $50.06 | -25,000 | 548,726 | -4% | -$1,251,500 | ||||||
2019-01-04 | ESPR | Biotech Target N V | 10% | P - Purchase | $41.29 | +80,000 | 3,472,964 | +2% | +$3,303,256 | ||||||
2018-12-24 | ESPR | Biotech Target N V | 10% | P - Purchase | $39.91 | +50,000 | 3,392,964 | +1% | +$1,995,725 | ||||||
2018-12-17 | ESPR | Biotech Target N V | 10% | P - Purchase | $47.73 | +60,000 | 3,342,964 | +2% | +$2,864,070 | ||||||
| M | 2018-11-02 | ESPR | Boxer Capital, LLC | 10% | S - Sale | $56.38 | -100,000 | 1,101,250 | -8% | -$5,638,343 | |||||
| M | 2018-11-01 | ESPR | Newton Roger S | Dir | S - Sale | $50.07 | -2,827 | 573,726 | 0% | -$141,549 | |||||
| M | 2018-10-16 | ESPR | Newton Roger S | Dir | S - Sale | $50.02 | -22,173 | 576,553 | -4% | -$1,108,997 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |